Even biotechs aren't immune to the newly-challenging IPO market. Six companies were scheduled to price IPOs this past week, but only four entered the public market; one biotech postponed while another - the largest - withdrew its IPO plans. All four priced at or below the midpoint. There was also a spike in initial filings, with eight companies and one SPAC entering the IPO pipeline.
The top performer this week was Phase 3 oncology biotech Aprea Therapeutics (APRE), which priced an $85 million upsized IPO at the midpoint. While the company's lead candidate has yielded